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Abstract
Introduction: In 2014, the Government of Thailand recommended pre-exposure prophylaxis (PrEP) as an additional HIV pre-
vention programme within Thailand’s National Guidelines on HIV/AIDS Treatment Prevention. However, to date implementa-
tion and uptake of PrEP programmes have been limited, and evidence on the costs and the epidemiological and economic
impact is not available.
Methods: We estimated the costs associated with PrEP provision among men having sex with men (MSM) participating in a
facility-based, prospective observational cohort study: the Test, Treat and Prevent HIV Programme in Thailand. We created a
suite of scenarios to estimate the cost-effectiveness of PrEP and sensitivity of the results to the model input parameters,
including PrEP programme effectiveness, PrEP uptake among high-risk and low-risk MSM, baseline and future antiretroviral
therapy (ART) coverage, condom use, unit cost of delivering PrEP, and the discount rate.
Results: Drug costs accounted for 82.5% of the total cost of providing PrEP, followed by lab testing (8.2%) and personnel
costs (7.8%). The estimated costs of providing the PrEP package in accordance with the national recommendation ranges from
US$223 to US$311 per person per year. Based on our modelling results, we estimate that PrEP would be cost-effective when
provided to either high-risk or all MSM. However, we found that the programme would be approximately 32% more cost-
effective if offered to high-risk MSM than it would be if offered to all MSM, with an incremental cost-effectiveness ratio of US
$4,836 per disability-adjusted life years (DALY) averted and US$7,089 per DALY averted respectively. Cost-effectiveness
acceptability curves demonstrate that 80% of scenarios would be cost-effective when PrEP is provided solely to higher-risk
MSM.
Conclusion: We provide the first estimates on cost and cost-effectiveness of PrEP in the Asia-Pacific region, and offer insights
on how to deliver PrEP in combination with ART. While the high drug cost poses a budgeting challenge, incorporating PrEP
delivery into an existing ART programme could be a cost-effective strategy to prevent HIV infections among MSM in Thailand.
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1 | INTRODUCTION
HIV pre-exposure prophylaxis (PrEP) can reduce sexual and
parenteral transmission of HIV. The World Health Organiza-
tion recommends PrEP as part of a comprehensive HIV pre-
vention package including HIV testing, counselling, condoms,
lubricants, antiretroviral therapy (ART) for partners of people
living with HIV, voluntary medical male circumcision and harm
reduction interventions for people who use drugs [1]. Oral
PrEP has been shown to be cost-effective in settings where
the HIV incidence is >3 per 100 person-years and in some
settings at lower incidence [1-5]. Although the literature sug-
gests that drug costs of oral PrEP are lower than
antiretroviral (ARV) drug costs on the basis of cost per dose
and duration of use, funding the high cost of PrEP on top of
other prevention programmes remains one of the main chal-
lenges, especially in resource-constrained settings [6-9].
Thailand included PrEP as an HIV prevention tool within
their 2014 national HIV Treatment and Prevention Guidelines
[10]. This is to complement key components of their National
Operational Plan for Ending AIDS 2015 to 2019 including
increasing HIV testing coverage, facilitation of those who test
positive to initiate and stay on treatment, and to provide HIV
prevention services to those who test negative [11]. In Thai-
land, PrEP services are either available free of charge or at
low-cost at several locations [12]. As of June 2017, an
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estimated 1044 men having sex with men (MSM) had
received services from the fee-based PrEP-30 demonstration
project (1000 Thai Baht (THB) per month, around US$30),
implemented by the Thai Red Cross Society [12]. Around
1000 MSM and transgender (TG) women have enrolled in the
Princess PrEP project, which started in 2016 under the Thai
Royal patronage [12]. Another 100 MSM and TG women
were enrolled in PrEP2START, a government-initiated PrEP
scale-up programme, which has been implemented in eight
HIV high-burden provinces since November 2016, and which
aims to strengthen the public health system and to enhance
capacity of healthcare professionals in providing PrEP to
MSM and TG [13]. Under the PrEP2START programme drugs
are provided free of charge, but participants contributed to
laboratory services ranging from US$11 to US$28 annually
[13].
Evidence suggests that PrEP programmes have experienced
both challenges and successes. An assessment of the PrEP-30
project in early 2016 reported no new infections among PrEP
users during the first year of project implementation [13]. The
Princess PrEP project showed a 52% retention rate at six
months with a 97% adherence rate of ≥4 tablets per week
(N = 671) [12]. Another study reported willingness to use
PrEP among MSM and TG women ranging from 36% to 41%,
with 65% willing to pay a maximum of US$21.40 per month
for PrEP [13]. However, wider implementation has been lim-
ited and evidence on the epidemiological and economic
impact, and costs of PrEP implementation is not available.
While demonstration projects indicate feasibility of PrEP
implementation, significant challenges for scale-up of PrEP
services in Thailand will include securing the financial
resources to make PrEP more widely available and mobiliza-
tion of human resources to prescribe PrEP in a timely manner
[14].
The objectives of this study were to assess the cost of pro-
viding oral PrEP to MSM, and to estimate the epidemiological
impact and cost-effectiveness of oral PrEP for this target
group. This study adds new evidence to the existing literature
by estimating primary costs for delivering PrEP in facility-
based settings and investigating the impact of potential
parameters, including programme effectiveness, uptake, and
condom use on the cost-effectiveness of PrEP provision.
2 | METHODS
This study was approved by the Thailand Ministry of Public
Health (MOPH) Ethical Review Committee and as a non-
research programme evaluation by the U.S. Centers for Dis-
ease Control and Prevention (CDC). All procedures were in
compliance with the Helsinki Declaration, the Code of Federal
Regulations, Title 45, Part 46 (45 CFR §46), and local ethical
and legal requirements. A written enrolment consent form
was sought from potential participants in the cohort study.
Staff consent was not required.
2.1 | Prospective observational cohort study
In May 2015, the Thailand MOPH in collaboration with the
CDC launched the Test, Treat, and Prevent HIV Programme
to identify barriers to the immediate initiation of ART and the
use of PrEP. Participants were enrolled and followed from
1 May 2015 to 30 April 2018 including 1880 Thai MSM and
TG from the Khon Kaen, Lerdsin, Srinagarind University,
Thammasat University, and Udon Thani Hospitals across four
provinces (Bangkok, Khon Kaen, Pathum Thani and Udon
Thani). PrEP was also offered at Lerdsin and Thammasat
Hospitals [15].
2.2 | Cost analysis
We conducted a retrospective cost analysis of the Test, Treat
and Prevent HIV Programme from 1 June 2015 to 31 May
2016 to derive the cost associated with HIV testing and PrEP
services from a provider perspective. Costs of HIV testing and
PrEP services were collected by programmatic activity (HIV
testing and counselling, PrEP initiation and PrEP visit (adher-
ence counselling, physical check, clinic visit, prescribing drugs
and blood draw)), by input type (personnel, drugs and com-
modities, supplies, test kits, laboratory testing including crea-
tinine, hepatitis B, syphilis screening, biochemistry and
haematology), and by source of support (cohort study or
MOPH). We used a time and motion analysis to measure the
average time health and lab staff spent on each programmatic
activity session. To calculate personnel costs, we collected
information from facility and project staff on their salaries and
allowances, and assumed staff worked eight hours per day for
20 days each month. We based the cost of supplies and
equipment associated with laboratory testing on price per test
using the quotes from the suppliers of lab reagents multiplied
by the number of tests conducted during the study. The price
paid per test covers the cost of the laboratory equipment, ser-
vices, reagents and consumables for the term of the agree-
ment excluding capital expenditures. The cost of drugs and
commodities was determined by multiplying the MOPH unit
price with the quantities used. The study excluded costs asso-
ciated with HIV-related morbidity and mortality, as well as
morbidities and mortalities stemming from adverse events
associated with care and treatment, costs borne by the health
system, higher-level overhead costs, and building maintenance
and utility costs. Data on beneficiary volume were extracted
from the outcomes of the cohort study to derive the unit cost
per-person-per-year (ppy) by dividing the total cost of the
programme by the number of PrEP participants. Data collec-
tion was conducted from October to December 2016. All
costs were collected in THB and converted to U.S. dollars
(USD) at the market exchange rate (1 USD = 35.42174 THB)
for the period the cost was incurred.
2.3 | Impact and cost-effectiveness analysis
To estimate the epidemiological impact of providing PrEP
to MSM, we used the Optima HIV tool (v2.6.6, available at
hiv.optimamodel.com), which is a compartmental model of HIV
transmission and disease progression linked to a programmatic
response module for estimating the epidemiological and eco-
nomic impact of interventions [16,17]. Of the approximately
571,000 MSM in Thailand [18], about one-third are character-
ized as being high-risk on the basis of having engaged in con-
domless sex with casual or known HIV-positive partners
[19,20]. We created a model of the MSM population in Thai-
land disaggregated into low-risk and high-risk groups and
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populated the model with available country-specific data on
population sizes, sexual behaviour, and testing rates, disaggre-
gated by risk group where possible (Table 1). Non-context
specific parameters were also used to inform the model as
documented in the Optima HIV user guide [21]. We calibrated
the model to historical HIV prevalence estimates to produce
baseline estimates of the expected number of new HIV infec-
tions over the period from the beginning of 2017 to the end
of 2022 in the absence of PrEP.
We assumed a five-year implementation period (fiscal per-
iod 2017-2018 to 2021-2022) and measured HIV infections
and disability-adjusted life years (DALYs) averted under a
range of different scenarios around PrEP provision. DALYs
were calculated from the onset of infection and cost and
effects were discounted at an annual rate ranging from 1.5%
to 4.5%. Disability weights were obtained from the literature
[21].
A knowledge of the baseline level of ART coverage among
MSM is essential in assessing the impact and cost-effective-
ness of providing PrEP. In 2014, ART coverage among MSM
was reported as 7% [18], but this is likely to be an underesti-
mate as it only includes people who self-reported as MSM.
The ART coverage among the total population of Thailand was
approximately 60% [24]. To account for the uncertainty sur-
rounding coverage of ART among MSM, we assumed baseline
ART coverage of 30% and allowed coverage to vary between
the estimates for MSM and for the total population. We fur-
ther assumed that the scale-up in ART coverage over the five-
year PrEP implementation will not exceed 20 percentage
points. For example, if the baseline ART coverage is assumed
to be 7%, we allowed ART coverage levels in 2021 to 2022
to range between 7% and 27%. With the baseline ART cover-
age of 60%, we allowed 2021 to 2022 coverage levels to
range between 60% and 80%, with the upper range corre-
sponding to the achievement of the UNAIDS 90-90-90 treat-
ment targets.
We considered two core sets of scenarios based on the
parameters listed in Table 2, one in which PrEP will be pro-
vided to all MSM and one in which PrEP will only be provided
to high-risk MSM. The uptake of PrEP in each scenario is
linked to ART coverage levels, with PrEP uptake in each
scenario ranging from 0% up to the assumed levels of ART
coverage in 2021 to 2022. We consider the possible impact
of PrEP on sexual disinhibition by modelling the impact of
reductions in condom use among MSM. While we do not
specifically model the effects of other changes in sexual beha-
viour (for example, an increase in the number of partners), we
expect that the results would be similarly sensitive to other
forms of sexual disinhibition [25].
We ran 60,000 model simulations, in which samples of each
of the eight parameters listed in Table 2 were drawn from
uniform distributions over their allowable ranges, and calcu-
lated the total number of new HIV infections and DALYs that
were estimated over the implementation period for each sim-
ulation.
For the cost-effectiveness analysis, we calculated the cost
associated with each scenario by disaggregating the cost of
PrEP and ART. To derive the cost of the PrEP intervention,
we multiplied the number of HIV-negative MSM by the per-
centage of MSM receiving PrEP and then by the unit cost ppy
of the PrEP programme. We multiplied the number of HIV-
positive MSM by the percentage of MSM receiving ART, and
then by the unit cost ppy of the ART programme to estimate
the cost of ART provision. The median cost per person on
ART per year including ARV medicines of US$369.57 was
obtained from the Test, Treat and Prevent HIV Programme
costing study from the same cohort [26]. We used a cost-
effectiveness threshold of US$17,449, equal to three times
the gross domestic product (GDP) per capita [27] to deter-
mine the cost-effectiveness of PrEP [28].
3 | RESULTS
3.1 | Annual PrEP costs
From 1 June 2015 to 31 May 2016, 366 HIV-negative
MSM and TG participants were recruited at Lerdsin and
Thammasat University Hospitals to participate in the PrEP
sub-study. Of the 366 participants, 163 (44.5%) accepted
PrEP free-of-charge for 12 months, and this was used to
determine the acceptance rate and to assess costs. Drug
costs accounted for 82.5% of the total annual costs
Table 1. Key parameters for the epidemiological model
Parameter Value Source and notes
Condom use among MSM with casual partners 82% 2015 [18]
Condom use among MSM with regular partners 66% Condom use with all male steady partners, value consistent from
2005 and 2007 [22]
Per-act transmission probabilities Varying [21]
Efficacy of interventions Varying [21]
Percentage MSM tested for HIV in the last 12 months 30.85% 2015 [23]
HIV prevalence among MSM
High-risk 11.6% 2017 [23]
Low-risk 5.2% 2017 [23]
Population size
High-risk 155,149 2017 [23]
Low-risk 362,055 2017 [23]
MSM, men having sex with men.
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associated with PrEP provision (Table 3). HIV testing costs
were US$824 per year. The unit cost ppy, including HIV
testing for all clinic visits and the cost of project staff who
provided PrEP was US$129. Project staff were hired to sup-
port PrEP services, but if the PrEP programme is imple-
mented, project staff will be replaced by MOPH staff. The
average unit cost of providing PrEP ppy without project staff
is US$128. We assumed that the unit cost of providing PrEP
to MSM will be the same as that derived for MSM/TG from
the cohort study.
We projected the cost if each participant took PrEP contin-
uously over the 12-month study period, attended clinic and
monitoring visits, and received HIV and lab tests following
recommended PrEP programme guidelines [29]. We applied a
micro costing approach to estimate the unit cost ppy and
quantities for personnel, HIV and lab testing, and drugs for
each package (Table 4). We applied a 0.7% proportion of over-
head costs from a similar existing study in Thailand [30] to
the unit cost. In the cohort study, demand creation activities
were included in each counselling session. Personal communi-
cations with a programme officer from a pilot PrEP project
conducted previously in Thailand indicated that the spending
for demand creation activities for both HIV testing and PrEP
accounted for approximately 22% of the project budget.
Although the amount included demand creation activities for
PrEP (inclusive of activities during the counselling session) and
for HIV testing, we applied this proportion to the unit cost to
reflect additional demand creation activities that may be
offered. The cost to implement the PrEP programme ranges
from US$222.89 to US$310.99 ppy depending on the pack-
age options and demand creation activities chosen.
3.2 | Impact and cost-effectiveness of PrEP
In Table 5 we present results on the number of HIV infec-
tions averted, lifetime treatment costs averted, and the
incremental cost-effectiveness ratio (ICER) for both HIV
infections and DALYs averted over the five-year
Table 2. Model parameters for PrEP implementation scenarios
Parameter Value Range Notes
PrEP programme effectiveness 75% 50% to 95% The variation in programme effectiveness reflects
uncertainty in both drug efficacy and adherence/
retention.
Baseline ART coverage among
MSM in 2017/18
30% 7% to 60% ART coverage among MSM in 2014 was reported at 7%
[18] (likely to be underestimated as this only includes
ART clients who self-reported as MSM). ART coverage
was approximately 60% among the total population [24].
We used a default value of 30% and allowed coverage
to vary between the estimates for MSM and for the
total population.
ART scale-up relative to baseline 10 ppts increase 0 to 20 ppts increase We set ART coverage among MSM in 2021/22 relative to
the value in 2017/18. Our default assumption is for a
slight scale-up relative to baseline; we contrast this with
maintenance of baseline levels and a larger increase.
Since our baseline ART coverage assumptions range up
to 60%, an assumption of a 20 percentage point scale-
up encompasses the accomplishment of the UNAIDS
90-90-90 targets.
PrEP uptake among high-risk MSM 10 ppts lower than
ART coverage levels
From 0% up to
ART coverage levels
As a baseline, we assume that PrEP uptake will be 10
percentage points lower than ART coverage levels. We
consider uptake values ranging from 0% up to ART
coverage levels.
PrEP uptake among low-risk MSM
Scenario: PrEP is provided to all
HIV-negative MSM
10 ppts lower than
ART coverage levels
From 0% up to
ART coverage levels
Scenario: PrEP is provided to
HIV-negative high-risk MSM
0% No range No uptake among low-risk MSM
Percentage reduction in condom
use for those receiving PrEP
10% 0% to 20% Moderate reduction in condom use in the moderate
scenario, no reduction in the ambitious scenario and
20% reduction in the conservative scenario.
PrEP unit cost ppy US$222.18 US$180 to US$310
Annual discounting rate 3% 1.5% to 4.5%
MSM, men having sex with men; PrEP, pre-exposure prophylaxis; ART, antiretroviral therapy; ppy, per-person-per-year; ppts, percentage points.
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implementation period. Results are presented for two core
implementation strategies: PrEP for high-risk MSM only and
PrEP for all MSM, and are based on the scenarios gener-
ated using the parameter values shown in Table 2. Compar-
ing these two strategies, we estimate that providing PrEP
to all MSM would have a greater epidemiological and eco-
nomic impact than providing PrEP to high-risk MSM only,
with almost 2.5 as many HIV infections averted (1368 vs.
555) and more than twice the discounted lifetime treatment
costs averted (US$9.84 million vs. US$3.99 million). How-
ever, providing PrEP only to high-risk MSM would be
approximately 32% more cost-effective than providing it to
all MSM, with ICERs of US$4,836 and US$7,089 per DALY
averted respectively. Applying the cost-effectiveness thresh-
old of three times GDP per capita of US$17,449, the
ICERs per DALY averted for both targeting strategies
demonstrate the cost-effectiveness of PrEP services.
3.3 | Sensitivity analysis
Figure 1 presents tornado diagrams summarizing the one-way
sensitivity analysis of the ICERs for both HIV infections and
DALYs averted based on the model parameters defined in
Table 2. The ICERs are particularly sensitive to both baseline
ART coverage and the ART scale-up rate. Higher ART baseline
coverage and a more rapid scale-up of ART would make the
PrEP programme relatively less cost-effective. These results
are also sensitive to the PrEP programme unit cost. In scenar-
ios where PrEP was only provided to high-risk MSM with all
other parameter values as indicated in Table 2, the ICER for
HIV infections averted is estimated to lie between US$58,670
and US$83,587, while the ICER for DALYs averted is estimated
to lie between US$3,767 and US$6,946. We estimate that
these ranges would increase to US$78,855 to US$142,828 and
US$5,266 to US$9,559 respectively if PrEP was provided to all
MSM. We also find that the scenario for providing PrEP only to
high-risk MSM, if condom use while using PrEP were main-
tained, would be particularly cost-effective.
Using a cost-effectiveness threshold of three times GDP
per capita, an estimated 80% of PrEP implementation scenar-
ios (as constructed using the parameter values from Table 2)
are calculated to be cost-effective if the PrEP programme is
provided solely to high-risk MSM, compared to 66% for all
MSM (Figure 2). The minimum and maximum ICERs for
DALYs averted are estimated to be US$702 (assuming a PrEP
unit cost of US$180, 95% PrEP programme effectiveness, no
reduction in condom usage, ART coverage remaining constant
at 7%, and a 1.5% discount rate) and US$218,802 ($310 PrEP
unit cost, 55% PrEP programme effectiveness, 20% reduction
in condom usage, 60% ART coverage increasing to 80% by
2021 to 2022, and a 4.5% discount rate) respectively.
4 | DISCUSSION
There is strong evidence for the safety and efficacy of PrEP
among MSM and other high-risk groups [2,31]. However, the
evidence on cost-effectiveness of PrEP is mixed, with results
varying depending on the unit cost of PrEP, population tar-
geted, and the broader health system context [32]. This sug-
gests that country-specific cost-effectiveness analyses may be
needed to inform national policy on PrEP implementation
Table 3. Distribution of total annual costs (USD) associated
with PrEP initiation and clinic visits by input type
Input type
Cohort study
(including MOPH
and project staff)
Projection
(MOPH staff only)
Personnel (health and
laboratory staff)
$1,452 (8.4%) $1,337 (7.8%)
Lab supplies and reagents $1,406 (8.2%) $1,406 (8.2%)
PrEP drugs $14,106 (82.0%) $14,106 (82.5%)
Other supplies $242 (1.4%) $242 (1.4%)
Total $17,206 $17,091
USD, U.S. dollars; PrEP, pre-exposure prophylaxis; MOPH, Ministry of
Public Health.
Table 4. Unit cost (USD) of PrEP recommended package by option per person per year
Cost category Option 1a Option 2b
Personnel (health and laboratory staff) to provide HIV testing and counselling,
one visit for initial PrEP counselling and recruitment, six visits of maintenance
support (counselling), four additional HIV tests, two creatinine tests, one
Hepatitis B surface antigen (HBs Ag) test and two upgraded STIs screenings (option 2 only)
$24.66 $25.63
Supplies (HIV testing and lab testing) for five HIV tests (initiating testing and four
additional tests), two creatinine tests, one HBs Ag test and two upgraded STIs screenings (option 2 only)
$10.36 $41.41
Tenofovir/Emtricitabine (TDF/FTC) (12 bottles: 1 pill per day) $186.33 $186.33
Total unit cost ppy $221.34 $253.37
Total unit cost ppy with overhead 0.7% $222.89 $255.14
Total unit cost ppy with overhead 0.7% and 22% demand creation activities $271.59 $310.88
USD, U.S. dollars; PrEP, pre-exposure prophylaxis; ppy, per-person-per-year.
aOption 1 package includes one visit for initial PrEP counselling and recruitment, four additional HIV tests, two tests for creatinine, one HBs Ag
test, 12 months TDF/FTC combination (tenofovir disoproxil fumarate/emtricitabine), six visits for maintenance support (counselling); bOption 2
package includes the option 1 package plus two times upgraded STIs screening (chlamydia, gonorrhoea, syphilis rapid test, nucleic acid amplifica-
tion test).
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strategies. Accordingly, a growing number of studies have
been published in recent years to fill this gap. We searched
PubMed from 1 January 2013 to 11 October 2017 with the
terms “HIV” AND (“PrEP” OR “PrEP”) AND (“cost” OR “cost-
effectiveness”) with the goal of identifying any new studies
that have appeared since the 2013 meta-analysis of PrEP
cost-effectiveness modelling studies [32]. The search retrieved
149 abstracts, of which 21 provided country-specific esti-
mates of the cost-effectiveness of various PrEP implementa-
tion strategies [6,8,9,33-49]. This study is not only the first to
provide data and evidence on the costs and cost-effectiveness
of providing oral PrEP to MSM in Thailand, but is also the
first such study from the Asia-Pacific region.
The unit cost of the PrEP programme in the cohort study
was lower than that of the recommended package because
not all study participants attended clinic visits quarterly and
took PrEP continuously, and the visit and testing schedules
were different between the cohort study and recommenda-
tion. Since PrEP was offered as an integrated service to
ART services in the study, the cost difference attributed to
project staff was less than US$1 per person-year. Consis-
tent with findings from other countries [32], drug costs rep-
resent the majority of PrEP programme costs. If the PrEP
programme could be delivered according to the recom-
mended package at a unit cost of US$222.89 ppy and pro-
vided to high-risk MSM, we estimate that it would be a very
cost-effective package, with an estimated ICER of US$4,836
per DALY averted, lower than Thailand’s per-capita GDP of
US$5,816. Through a sensitivity analysis we estimate that if
the PrEP programme is only provided to high-risk MSM,
80% of the scenarios that we considered would be cost-
effective, compared to 66% if the programme is provided to
all MSM.
There are several limitations to this study. The cost associ-
ated with community-based outreach activities, such as
demand creation and peer support groups (e.g. to improve
high-risk MSM enrolment or adherence) were not available
and were not implemented in the cohort study. We applied
the cost of demand creation activities based on the informa-
tion from another project and included overhead costs
obtained from another study as a proxy to define the range
of unit costs. The project engaged senior facility staff during
implementation, and the cost per person per year may be
lower if less senior staff were deployed. Laboratory testing
requirements varied among the facilities included in this
study. The proportion of lab costs from the recommended
PrEP package were much less than the project costs due to
the type and quantity of tests used in this study. In our
study, most tests were conducted quarterly and other tests,
such as biochemical tests were also included. Our analysis
did not consider new diagnostics, for example HIV self-test-
ing, which may lead to further reductions in cost. Costs
could be reduced if PrEP were offered on demand or for
less than 12 months. Due to limited resources, we did not
collect data on cost to clients, which would be useful to
determine the potential financial barriers and copayment.
Our sensitivity analysis attempted to account for cost varia-
tion due to outreach activities supporting adherence, drug
Table 5. Incremental cost-effectiveness ratios (ICERs) for core scenarios, based on the parameter values given in Table 2.
Scenario name
Cost Effectiveness ICERs
Total five-year
programme
cost (millions) DALYs averted HIV infections averted
Lifetime treatment
costs averted (million) $/DALY averted
$/HIV infection
averted
PrEP provided to
high-risk MSM
$41.99 7,857 555 $3.99 $4,836.00 $68,468.00
PrEP provided to
all MSM
$147.14 19,368 1368 $9.84 $7,089.00 $100,367.00
DALYs, disability-adjusted life years; $, U.S. dollars.
(a)
(b)
(c)
(d)
Figure 1. Tornado diagrams of univariate sensitivity analysis.
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prices, and duration of PrEP uptake. Not all possible factors
that may impact the cost-effectiveness of PrEP were
included – for example, we did not account for potential cost
savings or DALYs averted associated with screening for sexu-
ally transmitted infections, nor for the possible changes in
the number of partners that might result from PrEP uptake.
Instead we opted to model the impact of sexual disinhibition
as impacting condom use only. We expect that any additional
changes in sexual behaviour would impact the cost-effective-
ness of PrEP in a comparable way to the impact of changes
in condom use. While we did not consider the budget-impact
analysis, which will further guide the resource allocation deci-
sion, we have attempted to cost the PrEP programme and
have extrapolated the costs of the recommended package.
5 | CONCLUSIONS
This analysis provides insights on various PrEP delivery strate-
gies, as well as an analysis of some of the factors that influ-
ence PrEP impact and cost-effectiveness. These findings show
that the cost-effectiveness ratios are sensitive to ART cover-
age and PrEP programme effectiveness. A PrEP strategy tar-
geting high-risk MSM if condom use does not decrease was
found to be the most cost-effective intervention. Evidence
from both Thailand [13] and from other settings has consis-
tently shown no difference in condom use with uptake of
PrEP [31], so there is reason to be hopeful that the best-case
scenarios provided in this study would be reflected if PrEP
were implemented. While elevated PrEP drug costs will con-
tinue to pose a budgeting challenge, our results indicate that
providing PrEP to high-risk MSM is likely to be a cost-effec-
tive HIV prevention intervention.
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